Answers are grounded in this paper and cite their sources.
This study was undertaken to highlight neonatal Fc receptor inhibition (efgartigimod) as a valuable therapeutic option for patients with refractory seronegative myasthenia gravis (MG) and to emphasize the concept that seronegative MG is greatly constrained by the limitations of currently available diagnostic methods and therapeutic measures.
No takes yet. Share an insight, caveat, or question.
Sorrenti et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: